Interventions aiming at controlling hyperglycemia are the primary line of treatment for diabetic patients
Other weight-loss drugs are currently in development or regulatory approval stages, including: Once-daily GLP-1 pill orforglipron (Eli Lilly), which, when taken alongside a healthy diet and exercise, resulted in a 7.5% weight loss over 72 weeks on the 6mg dose, 8.4% loss with 12mg of orforglipron, and 11.2% loss with 36mg of orforglipron, as compared with 2.1% loss with placebo (funded by Eli Lilly
APAP induces hepatotoxicity, attenuates lipid peroxidation, and enhances antioxidant enzyme activation, including increases in interleukin (IL)-1, IL-6, and tumor necrosis factor- elevated (Yen et al., 2008)
That's where liposomal technology makes all the difference